Eli Lilly and Company $LLY Stock Position Lifted by Joel Isaacson & Co. LLC

Joel Isaacson & Co. LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 57.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 10,845 shares of the company’s stock after purchasing an additional 3,976 shares during the period. Joel Isaacson & Co. LLC’s holdings in Eli Lilly and Company were worth $8,275,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. KFG Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 7.3% during the second quarter. KFG Wealth Management LLC now owns 457 shares of the company’s stock worth $356,000 after buying an additional 31 shares during the last quarter. IronOak Wealth LLC. bought a new position in Eli Lilly and Company during the second quarter worth $2,032,000. Finally, Lederer & Associates Investment Counsel CA raised its stake in Eli Lilly and Company by 8.6% during the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 2,755 shares of the company’s stock valued at $2,148,000 after purchasing an additional 217 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. HSBC restated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Scotiabank assumed coverage on Eli Lilly and Company in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price target on the stock. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research note on Monday, January 5th. Finally, Daiwa America raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 16th. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Stock Up 0.2%

Shares of Eli Lilly and Company stock opened at $1,040.95 on Wednesday. The firm has a market cap of $984.09 billion, a PE ratio of 50.93, a P/E/G ratio of 0.78 and a beta of 0.35. The business’s 50 day simple moving average is $1,053.86 and its 200 day simple moving average is $875.14. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.